Protagonist Enterprise Value Over E B I T D A from 2010 to 2025
| PTGX Stock | USD 51.05 1.48 2.82% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 9.05741023 | Current Value 9.51 | Quarterly Volatility 6.12226786 |
Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 4.1 M or Selling General Administrative of 45.6 M, as well as many indicators such as Price To Sales Ratio of 5.2, Dividend Yield of 0.0 or PTB Ratio of 3.7. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
Protagonist | Enterprise Value Over E B I T D A |
Latest Protagonist Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Protagonist Therapeutics over the last few years. It is Protagonist Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Protagonist Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (4.38) | |
| Geometric Mean | 5.87 | |
| Coefficient Of Variation | (139.74) | |
| Mean Deviation | 4.26 | |
| Median | (6.57) | |
| Standard Deviation | 6.12 | |
| Sample Variance | 37.48 | |
| Range | 21.8634 | |
| R-Value | 0.41 | |
| Mean Square Error | 33.31 | |
| R-Squared | 0.17 | |
| Significance | 0.11 | |
| Slope | 0.53 | |
| Total Sum of Squares | 562.23 |
Protagonist Enterprise Value Over E B I T D A History
About Protagonist Therapeutics Financial Statements
Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 9.06 | 9.51 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.